Vital signs failing after cell therapy trial flop

13 September 2018

Bad news from Vital Therapies’ (Nasdaq: VTL) ongoing VTL-308 study has torpedoed the firm’s cell-based ELAD therapy, with the firm announcing on Wednesday that the trial had missed it primary endpoint.

Vital said it “does not believe the ELAD System can be approved in the USA or Europe, if ever, without additional clinical trials,” and that it would therefore “cease any further development,” and “explore strategic options.”

Not what the market wanted to hear, investors wasted little time offloading the firm’s stock in pre-market trading, sending the share price down over 90%, to just half a dollar.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK